CD274 and neoplasm: In POPLAR and OAK trials, assessing PD-L1 expression in tumor cells and tumor-infiltrating immune cells led to the finding that higher PD-L1 levels in both tumor cells and tumor-infiltrating immune cells were associated with improved patient survival after ICI therapy [25,94].